CAS NO: | 13957-31-8 |
包装 | 价格(元) |
5mg | 电议 |
25mg | 电议 |
100mg | 电议 |
250mg | 电议 |
Physical Appearance | A crystalline solid |
Storage | Store at -20°C |
M.Wt | 260.27 |
Cas No. | 13957-31-8 |
Formula | C9H12N2O5S |
Solubility | ≥107.8 mg/mL in DMSO; ≥25.85 mg/mL in EtOH; ≥44.8 mg/mL in H2O |
Chemical Name | 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-4-thioxo-3,4-dihydropyrimidin-2(1H)-one |
Canonical SMILES | OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C=CC(NC2=O)=S)O1 |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
4-Thiouridine is a photoactivatable ribonucleoside analog [1].
4-Thiouridine at high concentrations (> 100 μM) is used for various RNA analyses such as photoactivatable-ribonucleoside-enhanced crosslinking and immunoprecipitation, as well as nascent messenger RNA (mRNA) labeling [1].
In 2fTGH cells, 4-thiouridine at low concentrations ≤ 10 μM could be used to measure production and processing of ribosomal RNA (rRNA). However, in U2OS cells, elevated concentrations of 4-thiouridine (> 50 μM), commonly used for mRNA labeling experiments, inhibited production and processing of 47S rRNA, which was accompanied by induction of tumor suppressor p53, nucleoplasmic translocation of nucleolar nucleophosmin, and inhibition of cell proliferation [1].
In anin vivo model of Sephadex (SDX)-induced lung inflammation with Sprague–Dawley rats, 4-thiouridine (50 mg /kg, via intratracheal instillation) caused a 38.5% reduction of lung edema. Co-administration of 4-thiouridine at 50 mg /kg reduced total leukocyte count by 58%, and led to reductions in all leukocyte groups [2].
References:
[1]. Burger K, Mühl B, Kellner M, et al. 4-Thiouridine inhibits rRNA synthesis and causes a nucleolar stress response. RNA Biology, 2013, 10(10): 1623-1630.
[2]. Uppugunduri S, Gautam C. Effects of uridine, isomatitol and 4-thiouridine on in vitro cell adhesion and in vivo effects of 4-thiouridine in a lung inflammation model. International Immunopharmacology, 2004, 4(9): 1241-1248.